Protocol Number:
AC-055-503
Study Name:
US-Based, Observational Drug Registry of Opsumit® (Macitentan) New Users in Clinical Practice
Age Group:
Adult
Background Information:
See full details
Protocol Number:
13-CC-0012
Study Name:
A Natural History Study of Novel Biomarkers in Pulmonary Arterial Hypertension
Age Group:
Adult
Background Information:
Patients with PAH (Group 1) will be recruited to the National Institutes of Health (NIH) and enrolled in this natural history study investigating the ability of circulating markers of vascular inflammation as well as high-resolution cardiac magnetic resonance imaging (MRI) to accurately stage severity of disease and/or predict clinically relevant outcomes.
See full details
Protocol Number:
Study Name:
A Multi-Center Registry of Patients with Group 1 or Group 5 Pulmonary Arterial Hypertension
Age Group:
Adult
Background Information:
See full details
Protocol Number:
12-CC-0211
Study Name:
A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial Hypertension
Age Group:
Adult
Background Information:
See full details
Protocol Number:
RIN-PH-201
Study Name:
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease (INCREASE)
Age Group:
Adult
Background Information:
The purpose of this research study is to investigate the safety and how well inhaled treprostinil works in subjects with PH associated with interstitial lung disease (ILD) or combined pulmonary fibrosis and emphysema (CPFE).
National Clinical Trial (NCT) identifier on clinicaltrials.gov: NCT02630316
See full details
Protocol Number:
AC-065A402
Study Name:
SPHERE Uptravi® (SelexiPag): tHe usErs dRug rEgistry (SPHERE)
Age Group:
Adult
Background Information:
To develop and maintain a database of de-identified patient medical information and other related information in order to better assess and optimize outcomes for patients diagnosed with PAH and receiving treatment with Uptravi®.
Age Group: Patients ≥ 18 years of age at time of Uptravi initiation.
National Clinical Trial (NCT) identifier on clinicaltrials.gov: NCT03278002
See full details
Protocol Number:
NCT02587325
Study Name:
ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension
Age Group:
Adult
Background Information:
See full details
Protocol Number:
LTI-301
Study Name:
A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group I) Patients
This study is in follow-up
Age Group:
Adult
Background Information:
The purpose of this study to evaluate the long-term safety and tolerability of inhaled LIQ861 (treprostinil) using a dry powder inhaler.
National Clinical Trial (NCT) identifier on clinicaltrials.gov: NCT03399604
Principle Investigator: Oksana Shlobin, MD
See full details
Protocol Number:
Study Name:
Pulmonary Hypertension Association Registry (PHAR)
Age Group:
Adult
Background Information:
The goal of the PHAR is to measure and improve quality of care (including assessing differences in adherence to evidence-based guidelines and establishing benchmarks for health outcomes) while determining the clinical effectiveness, comparative effectiveness, and cost effectiveness of treatment approaches.
See full details